NCT00028834View on ClinicalTrials.gov

Bevacizumab and Gemcitabine in Treating Patients With Advanced Pancreatic Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

February 28, 2002

Primary Completion Date

December 31, 2004

Conditions
Adenocarcinoma of the PancreasRecurrent Pancreatic CancerStage III Pancreatic CancerStage IV Pancreatic Cancer
Interventions
DRUG

gemcitabine hydrochloride

Given IV

BIOLOGICAL

bevacizumab

Given IV

OTHER

laboratory biomarker analysis

Correlative studies

Trial Locations (1)

60637-1470

University of Chicago Comprehensive Cancer Center, Chicago

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00028834 - Bevacizumab and Gemcitabine in Treating Patients With Advanced Pancreatic Cancer | Biotech Hunter | Biotech Hunter